IBO
Price
$0.71
Change
+$0.02 (+2.90%)
Updated
Jul 25, 04:59 PM (EDT)
Capitalization
8.58M
LPCN
Price
$3.44
Change
+$0.12 (+3.61%)
Updated
Jul 25, 04:59 PM (EDT)
Capitalization
17.76M
Interact to see
Advertisement

IBO vs LPCN

Header iconIBO vs LPCN Comparison
Open Charts IBO vs LPCNBanner chart's image
Impact BioMedical
Price$0.71
Change+$0.02 (+2.90%)
Volume$500
Capitalization8.58M
Lipocine
Price$3.44
Change+$0.12 (+3.61%)
Volume$100
Capitalization17.76M
IBO vs LPCN Comparison Chart in %
Loading...
IBO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LPCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IBO vs. LPCN commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBO is a StrongBuy and LPCN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (IBO: $0.69 vs. LPCN: $3.32)
Brand notoriety: IBO and LPCN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBO: 3% vs. LPCN: 109%
Market capitalization -- IBO: $8.58M vs. LPCN: $17.76M
IBO [@Biotechnology] is valued at $8.58M. LPCN’s [@Biotechnology] market capitalization is $17.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $309.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBO’s FA Score shows that 0 FA rating(s) are green whileLPCN’s FA Score has 0 green FA rating(s).

  • IBO’s FA Score: 0 green, 5 red.
  • LPCN’s FA Score: 0 green, 5 red.
According to our system of comparison, both IBO and LPCN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBO’s TA Score shows that 5 TA indicator(s) are bullish while LPCN’s TA Score has 6 bullish TA indicator(s).

  • IBO’s TA Score: 5 bullish, 4 bearish.
  • LPCN’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, LPCN is a better buy in the short-term than IBO.

Price Growth

IBO (@Biotechnology) experienced а -1.02% price change this week, while LPCN (@Biotechnology) price change was +4.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.76%. For the same industry, the average monthly price growth was +19.76%, and the average quarterly price growth was +29.65%.

Reported Earning Dates

IBO is expected to report earnings on May 14, 2025.

LPCN is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+8.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LPCN($17.8M) has a higher market cap than IBO($8.58M). LPCN YTD gains are higher at: -31.967 vs. IBO (-52.372). LPCN has higher annual earnings (EBITDA): -6.42M vs. IBO (-22.79M). LPCN has more cash in the bank: 19.7M vs. IBO (1.32M). LPCN has less debt than IBO: LPCN (1.48M) vs IBO (9.14M). LPCN has higher revenues than IBO: LPCN (3.68M) vs IBO (0).
IBOLPCNIBO / LPCN
Capitalization8.58M17.8M48%
EBITDA-22.79M-6.42M355%
Gain YTD-52.372-31.967164%
P/E Ratio8.10N/A-
Revenue03.68M-
Total Cash1.32M19.7M7%
Total Debt9.14M1.48M617%
FUNDAMENTALS RATINGS
IBO vs LPCN: Fundamental Ratings
IBO
LPCN
OUTLOOK RATING
1..100
420
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
35
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
6564
P/E GROWTH RATING
1..100
9897
SEASONALITY SCORE
1..100
30n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LPCN's Valuation (35) in the Pharmaceuticals Other industry is in the same range as IBO (44) in the null industry. This means that LPCN’s stock grew similarly to IBO’s over the last 12 months.

LPCN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as IBO (100) in the null industry. This means that LPCN’s stock grew similarly to IBO’s over the last 12 months.

LPCN's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as IBO (99) in the null industry. This means that LPCN’s stock grew similarly to IBO’s over the last 12 months.

LPCN's Price Growth Rating (64) in the Pharmaceuticals Other industry is in the same range as IBO (65) in the null industry. This means that LPCN’s stock grew similarly to IBO’s over the last 12 months.

LPCN's P/E Growth Rating (97) in the Pharmaceuticals Other industry is in the same range as IBO (98) in the null industry. This means that LPCN’s stock grew similarly to IBO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBOLPCN
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 11 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
70%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
IBO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LPCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IBRX3.010.02
+0.67%
ImmunityBio
SIGA7.06-0.10
-1.40%
SIGA Technologies
CSPI11.57-0.31
-2.61%
CSP
BLBX7.30-0.20
-2.67%
Blackboxstocks
GGG84.84-2.34
-2.68%
Graco

IBO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBO has been loosely correlated with ITOS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if IBO jumps, then ITOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBO
1D Price
Change %
IBO100%
-2.73%
ITOS - IBO
45%
Loosely correlated
+0.20%
BMRN - IBO
42%
Loosely correlated
+0.15%
LPCN - IBO
27%
Poorly correlated
+1.53%
ADAG - IBO
23%
Poorly correlated
+3.29%
CHRS - IBO
22%
Poorly correlated
+4.23%
More

LPCN and

Correlation & Price change

A.I.dvisor indicates that over the last year, LPCN has been loosely correlated with SPRY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if LPCN jumps, then SPRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LPCN
1D Price
Change %
LPCN100%
+1.53%
SPRY - LPCN
63%
Loosely correlated
+1.88%
IPA - LPCN
43%
Loosely correlated
+26.92%
ZNTL - LPCN
36%
Loosely correlated
-2.65%
JANX - LPCN
31%
Poorly correlated
-1.85%
TARA - LPCN
30%
Poorly correlated
-1.47%
More